Oxford BioDynamics PLC Agreement with a major US biopharma company
November 07 2017 - 1:00AM
RNS Non-Regulatory
TIDMOBD
Oxford BioDynamics PLC
07 November 2017
7 November 2017
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the
"Group")
Oxford BioDynamics signs collaboration agreement with a major US
biopharmaceutical company
EpiSwitch(TM) technology to identify new targets and biomarkers
relating to fibrotic mechanisms
Fibrosis associated with chronic inflammation is a serious unmet
clinical need
Oxford BioDynamics Plc (AIM: OBD), a biotechnology company
focused on the discovery and development of epigenetic biomarkers
based on regulatory genome architecture, for use within the
pharmaceutical and biotechnology industry, is pleased to announce
that it has entered into an initial collaboration with a major US
biopharmaceutical company to advance the discovery and development
of novel treatments to address patients with abnormal wound healing
response, leading to fibrosis. Fibrosis is a pathological feature
of most chronic inflammatory diseases, which can affect nearly
every tissue in the body. If left to progress, the fibrotic process
eventually leads to organ malfunction and may ultimately result in
death.
The normal healing cascade in response to tissue injury involves
a series of sequential, timely and controlled physiological steps
which result in successful tissue repair and restoration of normal
function. Failure to control the multifaceted and complex healing
process can lead to considerable tissue remodelling resulting in
the replacement of functional tissue with permanent fibrous scar
tissue.
Under the terms of the collaboration agreement, the US
biopharmaceutical company will be granted access to OBD's unique
EpiSwitch(TM) technology for use in the analysis of
structure-function of genome architecture and new insights into
fibrotic mechanisms, new targets and new biomarkers. This will
support the development of novel therapeutic candidates and
next-generation companion diagnostics, and enable patient
population stratification for clinical trials in the area of
fibrosis.
Christian Hoyer Millar, Chief Executive Officer of Oxford
BioDynamics, said:
"We are pleased to be collaborating with a major global
biopharma company to support the development of potential novel
drug candidates, and the identification of patients suitable for a
new fibrosis treatment. This new collaboration is further evidence
of broad adoption of our validated proprietary technology
EpiSwitch(TM) for practical use in highly challenging therapeutic
development programmes."
-ENDS-
Oxford BioDynamics Plc +44 (0)1865 518910
Christian Hoyer Millar,
CEO
Paul Stockdale, CFO
Stifel Nicolaus Europe
Limited +44 (0)20 7710 7600
Nominated Advisor and
Broker
David Arch
Jonathan Senior
Peter Lees
Ben Maddison
Shore Capital +44 (0)20 7408 4090
Joint Broker
Stephane Auton
Edward Mansfield
FTI Consulting +44 (0)20 3727 1000
Financial Public Relations
Advisor
Julia Phillips
Brett Pollard
Natalie Garland-Collins
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
epigenetic biomarkers for use within the pharmaceutical and
biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes, and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the
London Stock Exchange's AIM under the ticker "OBD". For more
information please visit www.oxfordbiodynamics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUNVVRBWAARAA
(END) Dow Jones Newswires
November 07, 2017 02:00 ET (07:00 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024